Dyspnea on exertion in scleroderma: from symptom to diagnosis;Dyspnée à l'effort chez le patient atteint de sclérodermie systémique : du symptôme au diagnostic étiologique

Presse Medicale

Volumn 38, Issue 6, 2009, Pages 911-926

  Hachulla, Eric ^a   Bervar, Jean François ^a   Launay, David ^a   Lamblin, Nicolas ^a   Perez, Thierry ^a   Mouthon, Luc ^b   De Groote, Pascal ^a   Tillie Leblond, Isabelle ^a   Humbert, Marc ^c  

^a LILLE UNIVERSITY HOSPITAL   (France)

^b Institut Cochin   (France)

^c UNIVERSITÉ PARIS SACLAY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CAUSE OF DEATH; DIGESTIVE SYSTEM HEMORRHAGE; DYSPNEA; ECHOCARDIOGRAPHY; HEART CATHETERIZATION; HIGH RESOLUTION COMPUTER TOMOGRAPHY; HUMAN; INTERSTITIAL LUNG DISEASE; LUNG FUNCTION TEST; PULMONARY HYPERTENSION; QUESTIONNAIRE; SHORT SURVEY; SYSTEMIC SCLEROSIS; TASK PERFORMANCE; TRICUSPID VALVE REGURGITATION;

EID: 67349176634     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lpm.2008.08.017     Document Type: Short Survey

References (61)

1. ATS Board of Directors. Dyspnea: Mechanisms, assessment, and management: A consensus statement. Am J Respir Crit Care Med 159 (1999) 321-340
2. Karnani N.G., Reisfield G.M., and Wilson G.R. Evaluation of chronic dyspnea. Am Fam Physician 71 (2005) 1529-1537
3. Scano G., Stendardi L., and Grazzini M. Understanding dyspnoea by its language. Eur Respir J 25 (2005) 380-385
4. McGavin C.R., Artvinli M., Naoe H., and McHardy G.J.R. Dyspnoea, disability, and distance walked: comparison of estimates of exercise performance in respiratory disease. Br Med J 2 (1978) 241-243
5. Leiner G.C., Abramowitz S., Lewis W.A., and Small M.J. Dyspnea and pulmonary function tests. Am Rev Respir Dis 92 (1965) 822-823
6. Khanna D., Clements P.J., Furst D.E., Chon Y., Elashoff R., Roth M.D., et al. Correlation of the degree of dyspnea with health-related quality of life, functional abilities, and diffusing capacity for carbon monoxide in patients with systemic sclerosis and active alveolitis: results from the Scleroderma Lung Study. Arthritis Rheum 52 (2005) 592-600
7. Mahler D.A., Weinberg D.H., Wells C.K., and Feinstein A.R. The measurement of dyspnea. Contents, interobserver agreement, and physiologic correlates of two new clinical indexes. Chest 85 (1984) 751-758
8. Bestall J.C., Paul E.A., Garrod R., Garnham R., Jones P.W., and Wedzicha J.A. Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease. Thorax 54 (1999) 581-586
9. Mura M., Ferretti A., Ferro O., Zompatori M., Cavalli A., Schiavina M., and Fabbri M. Functional predictors of exertional dyspnea, 6-min walking distance and HRCT fibrosis score in idiopathic pulmonary fibrosis. Respiration 73 (2006) 495-502
10. Borg G. Simple rating methods for estimation of perceived exertion. Wenner-Gren Center International Symposium Series 1976; 28:39-47.
11. Badesch D.B., Abman S.H., Simonneau G., Rubin L.J., and McLaughlin V.V. Medical therapy for pulmonary arterial hypertension: updated ACCP evidence-based clinical practice guidelines. Chest 131 (2007) 1917-1928
12. Gibelin P. An evaluation of symptom classification systems used for the assessment of patients with heart failure in France. Eur J Heart Fail 3 (2001) 739-746
13. ATS statement: guidelines for the six-minute walk test. ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. Am J Respir Crit Care Med 166 (2002) 111-117
14. Tashkin D.P., Elashoff R., Clements P.J., Roth M.D., Furst D.E., Silver R.M., et al. Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease. Am J Respir Crit Care Med 176 (2007) 1026-1034
15. Mahler D.A., and Witek Jr. T.J. The MCID of the transition dyspnea index is a total score of one unit. Copd 2 (2005) 99-103
16. Hachulla E., Gressin V., Guillevin L., Carpentier P., Diot E., Sibilia J., et al. Early detection of pulmonary arterial hypertension in systemic sclerosis. A French nationwide prospective multicenter study. Arthritis Rheum 52 (2005) 3792-3800
17. Ghio S., Recusani F., Klersy C., Sebastiani R., Laudisa M.L., Campana C., et al. Prognostic usefulness of the tricuspid annular plane systolic excursion in patients with congestive heart failure secondary to idiopathic or ischemic dilated cardiomyopathy. Am J Cardiol 85 (2000) 837-842
18. Meluzín J., Spinarová L., Bakala J., Toman J., Krejcí J., Hude P., et al. Pulsed Doppler tissue imaging of the velocity of tricuspid annular systolic motion ; a new, rapid, and non-invasive method of evaluating right ventricular systolic function. Eur Heart J 22 (2001) 340-348
19. Nishimura R., and Tajik A. Evaluation of diastolic filling of left ventricle in health and disease: Doppler echocardiography is the clinician's Rosetta Stone. J Am Coll Cardiol 30 (1997) 8-18
20. Pellegrino R., Viegi G., Brusasco V., Crapo R.O., Burgos F., Casaburi R., et al. Stratégies d'interprétation des explorations fonctionnelles respiratoires. Rev Mal Respir 24 3 Pt 2 (2007) S83-108 2
21. Steen V.D., Conte C., Owens G.R., and Medsger Jr. T.A. Severe restrictive lung disease in systemic sclerosis. Arthritis Rheum 37 (1994) 1283-1289
22. Mukerjee D., St George D., Knight C., Davar J., Wells A.U., Du Bois R.M., et al. Echocardiography and pulmonary function as screening tests for pulmonary arterial hypertension in systemic sclerosis. Rheumatology (Oxford) 43 (2004) 461-466
23. Steen V., and Medsger Jr. T.A. Predictors of isolated pulmonary hypertension in patients with systemic sclerosis and limited cutaneous involvement. Arthritis Rheum 48 (2003) 516-522
24. van der Lee I., Zanen P., Grutters J.C., Snijder R.J., and van den Bosch J.M. Diffusing capacity for nitric oxide and carbon monoxide in patients with diffuse parenchymal lung disease and pulmonary arterial hypertension. Chest. 129 (2006) 378-383
25. Perez T., Denis G., Bautin N., Debroucker V., Launay D., Hatron P.Y., et al. Intérêt du volume capillaire pulmonaire par la technique de la double diffusion CO-NO dans la sclérodermie systémique. Rev Mal Respir 24 (2007) 1S154
26. American thoracic society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American thoracic society (ATS), and the European Respiratory Society (ERS). Am J Respir Crit Care Med 161 (2000) 646-664
27. Villalba W.O., Sampaio-Barros P.D., Pereira M.C., Cerqueira E.M., Leme Jr. C.A., Marques-Neto J.F., and Paschoal I.A. Six-minute walk test for the evaluation of pulmonary disease severity in scleroderma patients. Chest 131 (2007) 217-222
28. Furst D., Khanna D., Matucci-Cerinic M., Clements P., Steen V., Pope J., et al. Systemic sclerosis - continuing progress in developing clinical measures of response. J Rheumatol 34 (2007) 1194-1200
29. Buch M.H., Denton C.P., Furst D.E., Guillevin L., Rubin L.J., Wells A.U., et al. Submaximal exercise testing in the assessment of interstitial lung disease secondary to systemic sclerosis: reproducibility and correlations of the 6-min walk test. Ann Rheum Dis 66 (2007) 169-173
30. Miyamoto S., Nagaya N., Satoh T., Kyotani S., Sakamaki F., Fujita M., et al. Clinical correlates and prognostic significance of six-minute walk test in patients with primary pulmonary hypertension. Comparison with cardiopulmonary exercise testing. Am J Respir Crit Care Med 161 (2000) 487-492
31. Redelmeier D.A., Bayoumi A.M., Goldstein R.S., and Guyatt G.H. Interpreting small differences in functional status: the Six Minute Walk test in chronic lung disease patients. Am J Respir Crit Care Med 155 (1997) 1278-1282
32. Sitbon O., Humbert M., Nunes H., Parent F., Garcia G., Hervé P., et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J Am Coll Cardiol 40 (2002) 780-788
33. Aguilaniu B., Richard R., Costes F., Bart F., Martinat Y., Stach B., et al. Méthodologie et Pratique de l'Exploration Fonctionnelle à l'eXercice (EFX). Rev Mal Respir 24 3 Pt 2 (2007) 2S111-2S160
34. Schwaiblmair M., Behr J., and Fruhmann G. Cardiorespiratory responses to incremental exercise in patients with systemic sclerosis. Chest 110 (1996) 1520-1525
35. Sudduth C.D., Strange C., Cook W.R., Miller K.S., Baumann M., and Collop N.A. Failure of the circulatory system limits exercise performance in patients with systemic sclerosis. Am J Med 95 (1993) 413-418
36. Sitbon O., Humbert M., Jaïs X., Ioos V., Hamid A.M., Provencher S., et al. Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation 14 (2005) 3105-3111
37. Watson M., Hally R.J., McCue P.A., Varga J., and Jiménez S.A. Gastric antral vascular ectasia (watermelon stomach) in patients with systemic sclerosis. Arthritis Rheum 39 (1996) 341-346
38. Steen V.D. Scleroderma renal crisis. Rheum Dis Clin North Am 22 (1996) 861-878
39. Helfrich D.J., Banner B., Steen V.D., and Medsger Jr. T.A. Normotensive renal failure in systemic sclerosis. Arthritis Rheum 32 (1989) 1128-1134
40. Steen V.D., and Medsger T.A. Changes in causes of death in systemic sclerosis, 1972-2002. Ann Rheum Dis 66 (2007) 940-944
41. American thoracic society/european respiratory society international multidisciplinary consensus classification of the idiopathic interstitial pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001. Am J Respir Crit Care Med 2002; 165:277-304.
42. Wells A.U., Cullinan P., Hansell D.M., Rubens M.B., Black C.M., Newman-Taylor A.J., et al. Fibrosing alveolitis associated with systemic sclerosis has a better prognosis than lone cryptogenic fibrosing alveolitis. Am J Respir Crit Care Med 149 (1994) 1583-1590
43. Scussel-Lonzetti L., Joyal F., Raynauld J.P., Roussin A., Rich E., Goulet J.R., et al. Predicting mortality in systemic sclerosis: analysis of a cohort of 309 French Canadian patients with emphasis on features at diagnosis as predictive factors for survival. Medicine (Baltimore) 81 (2002) 154-167
44. Steen V.D., and Medsger Jr. T.A. Severe organ involvement in systemic sclerosis with diffuse scleroderma. Arthritis Rheum 43 (2000) 2437-2444
45. Masi A.T., Rodnan G.P., Medsger T.A., Altman R., D'Angelo W., Fries J., et al. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 23 (1980) 581-590
46. Mouthon L., Garcia de la Pena-Lefebvre P., Chanseaud Y., Tamby M.C., Boissier M.C., and Guillevin L. Pathogénie de la sclérodermie : aspects immunologiques. Ann Med Int 153 (2002) 167-178
47. Desai S.R., Veeraraghavan S., Hansell D.M., Nikolakopolou A., Goh N.S., Nicholson A.G., et al. CT features of lung disease in patients with systemic sclerosis: comparison with idiopathic pulmonary fibrosis and nonspecific interstitial pneumonia. Radiology 232 (2004) 560-567
48. Bouros D., Wells A.U., Nicholson A.G., Colby T.V., Polychronopoulos V., Pantelidis P., et al. Histopathologic subsets of fibrosing alveolitis in patients with systemic sclerosis and their relationship to outcome. Am J Respir Crit Care Med 165 (2002) 1581-1586
49. Kim E.A., Lee K.S., Johkoh T., Kim T.S., Suh G.Y., Kwon O.J., et al. Interstitial lung diseases associated with collagen vascular diseases: radiologic and histopathologic findings. Radiographics 22 (2002) S151-S165
50. Steen V.D. Predictors of end stage lung disease in systemic sclerosis. Ann Rheum Dis 62 (2003) 97-99
51. Mukerjee D., St George D., Coleiro B., Knight C., Denton C.P., Davar J., et al. Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach. Ann Rheum Dis 62 (2003) 1088-1093
52. Simonneau G., Galiè N., Rubin L.J., Langleben D., Seeger W., Domenighetti G., et al. Clinical classification of pulmonary hypertension. J Am Coll Cardiol 43 12 Suppl. S (2004) 5S-12S
53. Humbert M., Sitbon O., Chaouat A., Bertocchi M., Habib G., Gressin V., et al. Pulmonary arterial hypertension in France: results from a National Registry. Am J Respir Crit Care Med 173 (2006) 1023-1030
54. Resten A., Maitre S., Humbert M., Rabiller A., Sitbon O., Capron F., et al. Pulmonary hypertension: CT of the chest in pulmonary venoocclusive disease. AJR Am J Roentgenol 183 (2004) 65-70
55. Johnson S.R., Patsios D., Hwang D.M., and Granton J.T. Pulmonary veno-occlusive disease and scleroderma associated pulmonary hypertension. J Rheumatol 33 (2006) 2347-2350
56. Rabiller A., Jaïs X., Hamid A., Resten A., Parent F., Haque R., et al. Occult alveolar haemorrhage in pulmonary veno-occlusive disease. Eur Respir J 27 (2006) 108-113
57. Launay D., and Hachulla E. Atteintes cardiaques et pulmonaires sclérodermiques. Rev Prat 52 (2002) 1901-1907
58. Birk M.A., and Zeuthen E.L. Phrenicus palsy in progressive systemic sclerosis. Br J Rheumatol 34 (1995) 684-685
59. Russel D.C., Maloney A., and Muir A.L. Progressive generalized scleroderma: respiratory failure from primary chest wall involvement. Thorax 39 (1981) 219-220
60. Hill C.L., Nguyen A.M., Roder D., and Roberts-Thomson P. Risk of cancer in patients with scleroderma: a population based cohort study. Ann Rheum Dis 62 (2003) 728-731
61. Chatterjee S., Dombi G.W., Severson R.K., and Mayes M.D. Risk of malignancy in scleroderma: a population-based cohort study. Arthritis Rheum 52 (2005) 2415-2424